Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

paclitaxel and hyaluronic acid

A water soluble, muco-adhesive co-formulation composed of the natural taxane paclitaxel conjugated to the naturally occurring proteoglycan hyaluronic acid, with potential antineoplastic activity. Upon intravesical administration of paclitaxel and hyaluronic acid, HA targets and binds to CD44 expressed on cancer cells. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and inhibiting cellular motility, mitosis, and replication in CD44-expressing tumor cells. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, is overexpressed in a variety of cancer cell types and plays a key role in tumor cell proliferation, migration and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Oncofid-P-B
paclitaxel-hyaluronic acid
paclitaxel/hyaluronic acid
Abbreviation:P-HA
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search